ASH 2022 Highlights Podcast

In this episode (14.36 minutes), Medicom’s correspondent covers 6 presentations from the Annual Meeting of the American Society of Hematology (ASH 2022), held in New Orleans (LA, US) from 10-13 December 2022.
The topics discussed are:

1. Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL
   Patients with newly diagnosed B-lineage acute lymphoblastic leukaemia (B-ALL) who were measurable residual disease (MRD)-negative showed an overall survival (OS) benefit if they were treated with a consolidation therapy of blinatumomab plus chemotherapy compared with chemotherapy alone. The authors concluded that these results represent a new potential standard-of-care for this group of patients.
2. Excellent results for triplet regimen in FLT3-mutated AML
   The triplet combination of azacitidine, venetoclax, and gilteritinib induced high response rates in patients with newly diagnosed or relapsed/refractory FLT3-mutated acute myeloid leukaemia (AML) in a phase 1/2 study.
3.  Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data
   Talquetamab demonstrated a favourable safety profile and promising response rates in a heavily pre-treated group of patients with multiple myeloma (MM) in the phase 1/2 MonumenTAL-1 study, even in those who received prior T cell redirection therapy. A phase 3 study is initiated to compare this investigational agent to approved therapies.
4. Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma
   In patients with previously untreated mantle cell lymphoma (MCL), autologous stem cell transplantation (ASCT) plus ibrutinib maintenance outperformed ASCT alone with regard to failure-free survival. Furthermore, ASCT alone did not prove to be superior to ibrutinib maintenance, but ibrutinib appears to be favoured over ASCT in terms of toxicity.
5. Efgartigimod successful in immune thrombocytopenia
   Efgartigimod significantly improved platelet counts in patients with primary immune thrombocytopenia (ITP), compared with placebo. Moreover, the phase 3 ADVANCE IV study showed that the study drug was well tolerated by the study participants.
6. Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care
   Iptacopan outperformed standard-of-care in patients with paroxysmal nocturnal haemoglobinuria (PNH) who had residual anaemia after anti-C5 standard-of-care treatment, results from the phase 3 Apply-PNH trial demonstrated. Together with the favourable safety profile of iptacopan, this agent presents itself as a potential practice-changing treatment for this patient group.

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers



Posted on 5 January, 20235 January, 2023